Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) – HC Wainwright cut their Q1 2026 EPS estimates for Fennec Pharmaceuticals in a research report issued on Monday, March 30th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will earn ($0.03) per share for the quarter, down from their previous estimate of $0.10. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q2 2026 earnings at $0.07 EPS, FY2026 earnings at $0.43 EPS, Q1 2027 earnings at $0.24 EPS and Q2 2027 earnings at $0.31 EPS.
Separately, B. Riley Financial raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Strong Buy”.
Fennec Pharmaceuticals Stock Up 0.4%
FRX opened at C$8.93 on Wednesday. Fennec Pharmaceuticals has a twelve month low of C$7.02 and a twelve month high of C$13.83. The company’s 50-day moving average price is C$10.47 and its two-hundred day moving average price is C$11.08. The stock has a market cap of C$307.86 million, a price-to-earnings ratio of -26.26 and a beta of 3.01.
Insiders Place Their Bets
In related news, Director Rostislav Christov Raykov sold 10,349 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of C$10.69, for a total value of C$110,630.81. Following the sale, the director directly owned 2,709,294 shares in the company, valued at approximately C$28,962,352.86. The trade was a 0.38% decrease in their position. Company insiders own 16.20% of the company’s stock.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
Further Reading
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
